Nature Communications (Jun 2022)

Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection

  • Amy R. Rappaport,
  • Sue-Jean Hong,
  • Ciaran D. Scallan,
  • Leonid Gitlin,
  • Arvin Akoopie,
  • Gregory R. Boucher,
  • Milana Egorova,
  • J. Aaron Espinosa,
  • Mario Fidanza,
  • Melissa A. Kachura,
  • Annie Shen,
  • Gloria Sivko,
  • Anne Van Abbema,
  • Robert L. Veres,
  • Karin Jooss

DOI
https://doi.org/10.1038/s41467-022-31005-z
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

Self-amplifying mRNA vaccines offer the benefit of driving potent immune responses at low doses, as the mRNA replicates intracellularly. Here, the authors report the preclinical evaluation of a self-amplifying mRNA SARS-CoV-2 vaccine in non-human primates.